三生製藥(01530.HK)2019年度收入升16%至53.2億元 特比澳銷售額保持強勢增長
格隆匯3月31日丨三生製藥(01530.HK)發佈年度業績,截至2019年12月31日止年度,收入增加16.0%至人民幣53.181億元;毛利增加18.5%至人民幣43.927億元,毛利率為82.6%;研發成本增加45.2%至人民幣5.266億元,佔收入比率為9.9%;母公司擁有人應占正常化純利增加19.4%至人民幣13.923億元;基本每股盈利人民幣0.38元。
根據披露,三生製藥為中國領先的生物製藥公司。集團作為中國生物製藥行業的先鋒,在研發、生產及營銷生物技術產品方面擁有豐富的經驗。集團的核心產品包括特比澳、益賽普及重組人促紅素(“rhEPO”)產品益比奧及賽博爾。所有四種產品均為中國內地市場領先的產品。特比澳為當今全球唯一商業化的重組人血小板生成素(“rhTPO”)產品。根據IQVIA1,2019年,按銷售額計,特比澳在中國內地血小板減少症治療市場的份額增至73.2%。益賽普為腫瘤壞死因子α抑制劑產品,2019年繼續佔據中國內地市場主導地位,市場份額為60.9%。憑藉兩種rhEPO產品,近20年來,集團一直為中國內地rhEPO市場龍頭,2019年共佔rhEPO市場份額41.6%。集團亦通過內部研究及開發及多項外部戰略合作增加產品而擴大治療領域。
2019年度,集團收入約同比增長約16.0%,該增加主要由於特比澳及小分子藥品的銷售額強勢增長。2019年度,集團的特比澳銷售額增至約人民幣23.229億元,同比增長約39.1%。增加主要由於:醫學界對特比澳的認可日增,以及自2017年9月開始實施《國家醫保目錄》後加速增長,令其銷量增加。2019年度,特比澳的銷售額佔集團貨品銷售總額約43.5%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.